Company news
Monopar Therapeutics Inc. news in 2024
Monopar Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 19, 2024
Monopar Therapeutics Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR 101 Lu Form 8 K
December 6, 2024
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 4, 2024
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
December 2, 2024
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 7, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
October 29, 2024
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
October 27, 2024
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
October 27, 2024
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 23, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
October 21, 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
October 14, 2024
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 6, 2024
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 11, 2024
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
August 26, 2024
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 20, 2024
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 13, 2024
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
August 8, 2024
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
August 8, 2024
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
July 8, 2024
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
June 24, 2024
Monopar and NorthStar Amend & Extend Collaboration
June 10, 2024
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
June 9, 2024
Monopar Announces CFO Succession
May 23, 2024
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
May 8, 2024
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
April 17, 2024
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
April 15, 2024
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
April 9, 2024
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
March 27, 2024
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
March 4, 2024
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
February 26, 2024
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
February 21, 2024
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
February 19, 2024
Decks in 2024
- EANM 2024
Conference · 13 slides · October 2024